PASADENA, Calif.--(BUSINESS WIRE)--
Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that
Arrowhead's president and chief executive officer Christopher Anzalone,
Ph.D., will present at the 2015 Barclays Global Healthcare Conference on
March 11, 2015 at 1:35 p.m. EST. Investors may access live and archived
versions of the audio webcast of this presentation on the Company's
website at http://ir.arrowheadresearch.com/events.cfm.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic
hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency, and partner-based programs in obesity and
oncology.